Besotivan treatment duration and effect evaluation guide

Belzutifan As a newHIF-2α inhibitor, its treatment course management and effect evaluation are gradually being standardized, especially its application in the treatment of VHL (von Hippel-Lindau) disease-related tumors such as renal cell carcinoma (RCC) and central nervous system hemangioblastoma.

In terms of treatment duration, bestivan is usually designed as a long-term oral drug, administered continuously at a fixed dose once a day. This approach helps to continuously inhibit HIF-2α-mediated cancer-promoting signals, thereby achieving the goal of disease stabilization or remission. Since the drug is an oral preparation, its convenience in taking significantly improves patients' long-term medication compliance, making it particularly suitable for chronic tumor control strategies.

In terms of efficacy evaluation, current clinical judgments are mainly based on imaging standards (such asRECIST 1.1), tumor volume changes and improvement of related symptoms. The treatment response of kidney cancer patients usually appears after 2 to 3 months, and can be reexamined and evaluated through abdominal CT or MRI; for central nervous system lesions, brain MRI has become a key examination method. In most cases, bezotifan uses disease control rate (including partial response and stability) as the main efficacy indicator, with special emphasis on the delay of long-term disease progression.

In addition, based on the targeting of molecular mechanisms, some patients can see a decrease in biomarkers related to the HIF-2α pathway after taking the drug, such as the regulation of EPO levels or hemoglobin concentration. This is an indirect indicator of the drug's effect and may become an auxiliary parameter to evaluate sensitivity in the future.

It is worth noting that treatment management is not "one size fits all". If some patients experience clear adverse reactions or disease progression, dose reduction or suspension may be considered. Doctors will make flexible adjustments based on the pace of tumor progression and the patient's overall condition. Since bestivan is a new targeted drug with relatively controllable toxicity, most patients can use it for a long time. Especially in the context of VHL disease that requires lifelong management, its sustained and stable therapeutic effect is of great clinical value.

Reference materials:https://www.welireg.com/